OASL2_RAT
ID OASL2_RAT Reviewed; 511 AA.
AC Q5MYT9;
DT 05-SEP-2012, integrated into UniProtKB/Swiss-Prot.
DT 01-FEB-2005, sequence version 1.
DT 03-AUG-2022, entry version 94.
DE RecName: Full=2'-5'-oligoadenylate synthase-like protein 2;
DE EC=2.7.7.84;
GN Name=Oasl2;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA].
RC STRAIN=Sprague-Dawley; TISSUE=Ovary;
RX PubMed=12080145; DOI=10.1073/pnas.142287799;
RA Perelygin A.A., Scherbik S.V., Zhulin I.B., Stockman B.M., Li Y.,
RA Brinton M.A.;
RT "Positional cloning of the murine flavivirus resistance gene.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:9322-9327(2002).
RN [2]
RP REVIEW.
RX PubMed=17024523; DOI=10.1007/s00239-006-0073-3;
RA Perelygin A.A., Zharkikh A.A., Scherbik S.V., Brinton M.A.;
RT "The mammalian 2'-5' oligoadenylate synthetase gene family: evidence for
RT concerted evolution of paralogous Oas1 genes in Rodentia and
RT Artiodactyla.";
RL J. Mol. Evol. 63:562-576(2006).
CC -!- FUNCTION: Interferon-induced, dsRNA-activated antiviral enzyme which
CC plays a critical role in cellular innate antiviral response.
CC Synthesizes oligomers of 2'-5'-oligoadenylates (2-5A) from ATP which
CC then bind to the inactive monomeric form of ribonuclease L (RNase L)
CC leading to its dimerization and subsequent activation. Activation of
CC RNase L leads to degradation of cellular as well as viral RNA,
CC resulting in the inhibition of protein synthesis, thus terminating
CC viral replication. Can mediate the antiviral effect via the classical
CC RNase L-dependent pathway or an alternative antiviral pathway
CC independent of RNase L (By similarity). {ECO:0000250}.
CC -!- CATALYTIC ACTIVITY:
CC Reaction=3 ATP = 5'-triphosphoadenylyl-(2'->5')-adenylyl-(2'->5')-
CC adenosine + 2 diphosphate; Xref=Rhea:RHEA:34407, ChEBI:CHEBI:30616,
CC ChEBI:CHEBI:33019, ChEBI:CHEBI:67143; EC=2.7.7.84;
CC -!- COFACTOR:
CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000305};
CC -!- ACTIVITY REGULATION: Produced as a latent enzyme which is activated by
CC dsRNA generated during the course of viral infection. The dsRNA
CC activator must be at least 15 nucleotides long, and no modification of
CC the 2'-hydroxyl group is tolerated. ssRNA or dsDNA do not act as
CC activators (By similarity). {ECO:0000250}.
CC -!- SIMILARITY: Belongs to the 2-5A synthase family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AY237116; AAP70315.1; -; mRNA.
DR RefSeq; NP_001009682.1; NM_001009682.1.
DR AlphaFoldDB; Q5MYT9; -.
DR SMR; Q5MYT9; -.
DR STRING; 10116.ENSRNOP00000001600; -.
DR PaxDb; Q5MYT9; -.
DR PRIDE; Q5MYT9; -.
DR GeneID; 304549; -.
DR KEGG; rno:304549; -.
DR UCSC; RGD:1307351; rat.
DR CTD; 23962; -.
DR RGD; 1307351; Oasl2.
DR eggNOG; KOG0001; Eukaryota.
DR HOGENOM; CLU_040930_1_0_1; -.
DR InParanoid; Q5MYT9; -.
DR OrthoDB; 611234at2759; -.
DR PhylomeDB; Q5MYT9; -.
DR TreeFam; TF329749; -.
DR PRO; PR:Q5MYT9; -.
DR Proteomes; UP000002494; Unplaced.
DR GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR GO; GO:0016020; C:membrane; IBA:GO_Central.
DR GO; GO:0005654; C:nucleoplasm; IBA:GO_Central.
DR GO; GO:0001730; F:2'-5'-oligoadenylate synthetase activity; ISS:UniProtKB.
DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR GO; GO:0003725; F:double-stranded RNA binding; ISS:UniProtKB.
DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR GO; GO:0051607; P:defense response to virus; IBA:GO_Central.
DR GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR GO; GO:0045071; P:negative regulation of viral genome replication; IBA:GO_Central.
DR GO; GO:0060700; P:regulation of ribonuclease activity; IBA:GO_Central.
DR GO; GO:0009615; P:response to virus; TAS:UniProtKB.
DR CDD; cd05400; NT_2-5OAS_ClassI-CCAase; 1.
DR Gene3D; 3.30.460.10; -; 1.
DR InterPro; IPR018952; 2-5-oligoAdlate_synth_1_dom2/C.
DR InterPro; IPR026774; 2-5A_synthase.
DR InterPro; IPR006117; 2-5OAS_C_CS.
DR InterPro; IPR043518; 2-5OAS_N_CS.
DR InterPro; IPR006116; NT_2-5OAS_ClassI-CCAase.
DR InterPro; IPR043519; NT_sf.
DR InterPro; IPR000626; Ubiquitin-like_dom.
DR InterPro; IPR029071; Ubiquitin-like_domsf.
DR PANTHER; PTHR11258; PTHR11258; 1.
DR Pfam; PF10421; OAS1_C; 1.
DR Pfam; PF00240; ubiquitin; 1.
DR SMART; SM00213; UBQ; 2.
DR SUPFAM; SSF54236; SSF54236; 2.
DR SUPFAM; SSF81301; SSF81301; 1.
DR PROSITE; PS00832; 25A_SYNTH_1; 1.
DR PROSITE; PS00833; 25A_SYNTH_2; 1.
DR PROSITE; PS50152; 25A_SYNTH_3; 1.
DR PROSITE; PS50053; UBIQUITIN_2; 1.
PE 2: Evidence at transcript level;
KW Antiviral defense; ATP-binding; Immunity; Innate immunity; Magnesium;
KW Metal-binding; Nucleotide-binding; Nucleotidyltransferase;
KW Reference proteome; RNA-binding; Transferase.
FT CHAIN 1..511
FT /note="2'-5'-oligoadenylate synthase-like protein 2"
FT /id="PRO_0000418634"
FT DOMAIN 439..477
FT /note="Ubiquitin-like"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00214"
FT BINDING 69
FT /ligand="ATP"
FT /ligand_id="ChEBI:CHEBI:30616"
FT /evidence="ECO:0000250|UniProtKB:P00973"
FT BINDING 81
FT /ligand="Mg(2+)"
FT /ligand_id="ChEBI:CHEBI:18420"
FT /ligand_note="catalytic"
FT /evidence="ECO:0000255"
FT BINDING 83
FT /ligand="Mg(2+)"
FT /ligand_id="ChEBI:CHEBI:18420"
FT /ligand_note="catalytic"
FT /evidence="ECO:0000255"
FT BINDING 154
FT /ligand="Mg(2+)"
FT /ligand_id="ChEBI:CHEBI:18420"
FT /ligand_note="catalytic"
FT /evidence="ECO:0000255"
FT BINDING 213
FT /ligand="ATP"
FT /ligand_id="ChEBI:CHEBI:30616"
FT /evidence="ECO:0000250|UniProtKB:P29728"
FT BINDING 216
FT /ligand="ATP"
FT /ligand_id="ChEBI:CHEBI:30616"
FT /evidence="ECO:0000250|UniProtKB:P00973"
SQ SEQUENCE 511 AA; 59406 MW; F209B2D883AC7476 CRC64;
MDTLPDLYGT VGDSLDYFLE HSLQPQRDWK EEGKDAWERI ERFFREKCFC DELLLDQEVR
VLKVVKGGSS GKGTALNHRS DQDMILFLSC FSSFKQQARD RKAVIDFIKS KLIHCRKSLA
YNITVRQHKE GKRTPRSLTL EIQSRKSNDI ICMDILPAYN ALGSFSRDCK PEPEIYENLI
RCKGYPGDFS PSFAELQRHF VKSRPVKLKN LLRLVKFWHL KYLRHKYRRA VLPSKYALEL
LTIYAWEMGT DSSDNFNLDE GFVAVMELLR DYQDICIYWT KYYDFQNEVV RNFLKEQLKG
DRPIILDPAD PTNNLGRRGK WELVAKEATY CLLQLCCVTA DRWNVQVSIA HYLRGARDVQ
VTVKQTGREE WILLTNPHSP IRKLKAKIKK RMNLCGELRI SFQEPGGERQ PLSGRKTLSD
YGIFSKVNIR VMETFPPEIQ VFVRYPGGQN KPFAIDPDAT ILSLWEKIEE DGGPCTEDWV
LLFEGEELDD DDNLAELQIK DCDTIQLSRV S